Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

As federal oversight of compounded GLP-1 medications and research peptides continues to evolve at the U.S. Food and Drug Administration, a growing number of state legislatures and pharmacy boards are moving to impose their own, often stricter, rules on compounding pharmacies, telehealth prescribers, and the sale of injectable peptides. According to reporting from The National Law Review, this patchwork of state-level action is creating a increasingly complex compliance landscape for an industry that has expanded rapidly amid persistent shortages of brand-name GLP-1 drugs like semaglutide and tirzepatide.

The trend reflects a broader pattern seen throughout U.S. pharmaceutical regulation: when federal agencies move slowly or leave gaps, states step in to fill them—sometimes aggressively. For compounders, telehealth companies, and peptide sellers, that means the FDA's rules are no longer the only, or even the most restrictive, standard they must satisfy.

Why This Matters for the Peptide Industry

Compounded semaglutide and tirzepatide surged in popularity after GLP-1 drugs like Ozempic, Wegovy, and Zepbound became difficult to obtain due to manufacturing shortages. Compounding pharmacies, operating under exemptions in the Federal Food, Drug, and Cosmetic Act, stepped into that gap, along with a growing market of research peptides marketed for off-label use, longevity, and wellness purposes.

That growth, however, has drawn scrutiny. The FDA has taken enforcement actions against certain compounders and issued warnings about unapproved peptide products, but the agency's authority over compounding is inherently limited compared to its authority over approved drugs. States, which license pharmacies and regulate the practice of medicine within their borders, have far more direct tools to restrict, condition, or ban certain compounding and prescribing practices.

For businesses operating in this space, the result is a regulatory environment that varies significantly depending on where a pharmacy is licensed, where a prescriber is based, and where a patient resides—raising the stakes for compliance programs that historically may have focused primarily on federal requirements.

What State Regulators Are Doing

While specific requirements differ by jurisdiction, the National Law Review's analysis points to several recurring themes in how states are asserting authority "above the federal floor":

• Imposing additional licensing or registration requirements on compounding pharmacies that ship products into their states
• Restricting or clarifying the conditions under which telehealth prescribers can issue prescriptions for compounded GLP-1s
• Placing limits on marketing claims for peptide products, particularly those not approved by the FDA
• Increasing pharmacy board inspection and reporting obligations tied to sterile and non-sterile compounding practices
• In some cases, restricting the compounding of drugs that closely replicate FDA-approved products once shortages are declared resolved

This last point is particularly significant. Under federal law, pharmacies generally may compound versions of a drug only while it remains on the FDA's official shortage list. As shortages of tirzepatide and semaglutide have been declared resolved and then, in some cases, reinstated, compounders have faced shifting federal guidance—and state regulators have layered their own interpretations and enforcement priorities on top of that uncertainty.

What This Means

For companies and practitioners operating in the compounded GLP-1 and peptide space, the practical implications are substantial:

• Multi-state operations face compounding compliance burdens. A pharmacy compliant with federal 503A or 503B requirements may still run afoul of state-specific rules in jurisdictions where it ships product.
• Telehealth prescribing models require state-by-state legal review. Rules governing remote prescribing, informed consent, and physician-patient relationships vary widely and are subject to change.
• Marketing and labeling claims carry heightened risk. States are increasingly willing to act against claims that peptides or compounded GLP-1s are safe, effective, or equivalent to approved drugs absent FDA approval.
• Shortage-status volatility complicates long-term planning. Businesses built around compounding exemptions tied to shortage designations must monitor both FDA determinations and how individual states respond to them.

In short, legal compliance can no longer be evaluated solely through a federal lens. As the National Law Review piece underscores, the "federal floor" set by FDA regulation is increasingly just a starting point, with states building additional, sometimes more restrictive, layers on top.

Next Steps and What to Watch

Industry stakeholders should expect continued fragmentation rather than consolidation in the near term. Key developments to monitor include:

• Additional state pharmacy board rulemaking specifically targeting GLP-1 compounding and peptide sales
• Potential legislative action in state houses as lawmakers respond to constituent complaints, adverse events, or lobbying from both compounding pharmacies and brand-name manufacturers
• Further FDA guidance or enforcement actions that could either preempt certain state rules or prompt additional state-level responses
• Ongoing litigation involving compounders, manufacturers, and state regulators over the boundaries of permissible compounding activity

Companies operating in this space would be well advised to conduct jurisdiction-specific legal reviews rather than relying on a single national compliance framework, and to build monitoring systems capable of tracking both FDA shortage determinations and state regulatory changes in real time.

This article is for informational purposes only and does not constitute legal advice. Companies and individuals with specific compliance questions regarding compounded medications or peptide products should consult qualified regulatory counsel.